Co-Prenessa 2mg/0.625mg 30 tablets — Made in Slovenia — Free Delivery

Brand: KRKA
Product Code: Co-Prenessa 2mg/0.625mg
Availability: In Stock

$25.12

Add to Cart

Description

Indications

Essential hypertension.

Contraindications

Related to perindopril

Hypersensitivity to the active substance or to any other component of the preparation, as well as to other ACE inhibitors.
The presence of angioedema in history associated with previous treatment with ACE inhibitors.
Hereditary or idiopathic angioedema.
Pregnant women or women who plan to become pregnant.

Related to indapamide

Hypersensitivity to indapamide, other sulfonamides.
Severe renal failure (creatinine clearance below 30 ml/min).
Hepatic encephalopathy or severe liver dysfunction.
Hypokalemia.

Related to Co-Prenesa

Co-Prenesa 2mg/0.625mg, 4mg/1.25mg and 8mg/2.5mg

Hypersensitivity to the components of the preparation.

Due to the lack of sufficient therapeutic experience, Co-Prenes should not be used:

patients on hemodialysis.
patients with untreated decompensated heart failure.
Co-Prenesa, 2 mg / 0.625 mg
Severe renal dysfunction (creatinine clearance below 30 ml/min).
Co-Prenesa, 4 mg / 1.25 mg, co-Prenesa, 8 mg / 2.5 mg
Severe and moderate renal dysfunction (creatinine clearance below 60 ml/min).

Compound

active ingredients: perindopril tert-butylamine, indapamide

1 tablet contains perindopril tert-butylamine 2 mg and indapamide 0.625 mg, or perindopril tert-butylamine 4 mg and indapamide 1.25 mg, or perindopril tert-butylamine 8 mg and indapamide 2.5 mg

excipients: calcium chloride, lactose monohydrate hexahydrate, crospovidone microcrystalline cellulose sodium bicarbonate silicon dioxide aqueous magnesium stearate.

Dosage and administration

Co-Prenesa orally.

Co-Prenesa, 2 mg / 0.625 mg

The usual dose is 1 tablet of Co-Prenes, 2 mg/0.625 mg, daily as a single dose, preferably taken in the morning before meals. If blood pressure is not regulated within one month of treatment, the dose may be doubled. Ko-Prenesa 4 mg / 1.25 mg Tablets Ko-Prenesa 4 mg / 1.25 mg are indicated in patients whose blood pressure is not adequately controlled by perindopril monotherapy. The usual dose is 1 tablet of Co-Prenes, 4 mg/1.25 mg per day as a single dose, preferably taken in the morning before meals. If possible, individual titration of the dose of Co-Prenes by components is recommended. Co-Prenes 4 mg/1.25 mg tablet should be given when blood pressure is not adequately controlled with Co-Prenes 2 mg/0.625 mg tablets (when appropriate). In the presence of clinical indications, a decision is made to directly switch from monotherapy with perindopril to taking Co-Prenes tablets, 4 mg / 1.25 mg. Co-Prenesa 8 mg/2.5 mg Co-Prenesa 8 mg/2.5 mg tablets are indicated for the treatment of hypertension as a replacement in patients already taking perindopril and indapamide alone at the same doses. The usual dose is 1 tablet of Co-Prenes, 8 mg/2.5 mg per day as a single dose, preferably taken in the morning before meals. The maximum daily dose of Co-Prenes is 1 tablet of Co-Prenes, 8 mg/2.5 mg.

Special groups

Elderly patients (see Section "Peculiarities of use") Co-Prenes, 2 mg / 0.625 mg Treatment should begin with the usual dose - 1 tablet of Co-Prenes, 2 mg / 0.625 mg per day. Ko-Prenesa, 4 mg / 1.25 mg Treatment should be initiated according to the response of blood pressure and renal function. Ko-Prenesa, 8 mg / 2.5 mg In elderly patients, plasma creatinine levels should be adjusted according to age, body weight and sex. If renal function is normal, elderly patients can be treated according to the blood pressure response. Impaired renal function Co-Prenesa, 2 mg / 0.625 mg, 4 mg / 1.25 mg In severe renal impairment (creatinine clearance <30 ml / min), treatment with Co-Prenesa is contraindicated. For patients with moderate renal impairment (creatinine clearance 30-60 ml / min), it is recommended to start treatment with the appropriate doses of the individual components of Co-Prenesa. Patients with creatinine clearance ≥ 60 ml / min do not require dose adjustment. Routine medical supervision should include frequent monitoring of plasma creatinine and potassium levels. Co-Prenesa 8 mg / 2.5 mg In severe hepatic impairment (creatinine clearance <30 ml/min), treatment with Co-Prenesa is contraindicated. Patients with moderate hepatic impairment do not require dose adjustment. Impaired liver function In case of severe liver dysfunction, treatment with Co-Prenes is contraindicated. Patients with impaired liver function of an average degree of dose adjustment are not required.

CHILDREN

Co-Prenesa is not recommended for use in children due to the lack of safety and efficacy data for this group of patients.

0 reviews

There are no reviews for this product.